ASP Isotopes Inc./$ASPI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ASP Isotopes Inc.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
- Ticker
- $ASPI
- Sector
- Materials
- Primary listing
- NASDAQ
- Employees
- 271
- Headquarters
- Dallas, United States
- Website
- aspisotopes.com
ASPI Metrics
BasicAdvanced
$434M
-
-$1.22
3.60
-
Price and volume
Market cap
$434M
Beta
3.6
52-week high
$14.49
52-week low
$2.51
Average daily volume
4.4M
Financial strength
Current ratio
3.873
Quick ratio
3.692
Long term debt to equity
0.779
Total debt to equity
0.981
Interest coverage (TTM)
-24.66%
Profitability
EBITDA (TTM)
-91.506
Gross margin (TTM)
18.32%
Net profit margin (TTM)
-427.99%
Operating margin (TTM)
-312.31%
Effective tax rate (TTM)
-0.09%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-17.01%
Return on equity (TTM)
-90.35%
Valuation
Price to revenue (TTM)
9.936
Price to book
1.39
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
-3.668
Free cash flow yield (TTM)
-27.26%
Free cash flow per share (TTM)
-0.772
Growth
Revenue change (TTM)
573.43%
Earnings per share change (TTM)
-17.22%
3-year earnings per share growth (CAGR)
46.29%
Bulls say / Bears say
PET Labs reported organic revenue growth of more than 50% in the first half of 2026, and management forecast full-year revenue of about $14 million versus $6 million in 2025. That gives ASPI a growing revenue base while its newer isotope projects are still being commercialised. (Last10K)
The liquid-helium plant entered commissioning in August, and take-or-pay contracts then covered 15% of Phase 1 helium capacity and 75% of Phase 1 LNG capacity. Those agreements offer a route to sales as the project ramps, although commercial production and fuller capacity sales still need to be delivered. (GlobeNewswire)
ASPI has signed three commercial contracts for enriched Silicon-28, and it reported restarting the first 18 stages of its plant after making engineering changes. If the remaining stages work as planned, those customer contracts could support initial sales into semiconductor and quantum-computing markets. (ASP Isotopes)
ASPI lost $60.7 million from continuing operations in the first half of 2026 and used $40.0 million of cash in operating activities. Its cash and short-term investments provide a buffer, but the ongoing burn makes timely commercial growth important. (SEC.gov)
The company has acknowledged delays at its stable-isotope facilities, citing equipment problems, and reported an outage that set back Ytterbium-176 enrichment. Further commissioning setbacks could postpone shipments and delay revenue from these projects. (ASP Isotopes)
In July, ASPI exchanged $109.2 million of Quantum Leap Energy convertible notes for about 23.2 million ASPI shares. The deal reduces subsidiary debt, but expands the parent’s share count and dilutes existing holders. (SEC.gov)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
ASPI Financial Performance
Revenues and expenses
ASPI Earnings Performance
Company profitability
Upcoming events
No upcoming events
ASPI News
AllArticlesVideos
ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth
MarketBeat2 months ago
ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed
MarketBeat2 months ago
Aeternum Health Announces Change in Strategy, New Management, and Updates Investors on Progress
MCAP MediaWire2 months ago
Funds containing ASPI
AllEURGBPUSD
Fund name | Fund size | $ASPI weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.